Last reviewed · How we verify
HER2 Specific CAR T Cell — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
HER2 Specific CAR T Cell (HER2 Specific CAR T Cell) — Children's Oncology Group.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| HER2 Specific CAR T Cell TARGET | HER2 Specific CAR T Cell | Children's Oncology Group | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- HER2 Specific CAR T Cell CI watch — RSS
- HER2 Specific CAR T Cell CI watch — Atom
- HER2 Specific CAR T Cell CI watch — JSON
- HER2 Specific CAR T Cell alone — RSS
Cite this brief
Drug Landscape (2026). HER2 Specific CAR T Cell — Competitive Intelligence Brief. https://druglandscape.com/ci/her2-specific-car-t-cell. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing